{"id":"double-dose-quadrivalent-influenza-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated antigens from four influenza virus strains (two A subtypes and two B lineages) at twice the typical antigen dose per strain. The increased antigen load is designed to stimulate a more robust humoral and cellular immune response, potentially improving seroconversion rates and antibody titers, particularly in populations with diminished immune responses such as elderly or immunocompromised individuals.","oneSentence":"A quadrivalent influenza vaccine administered at double the standard dose to enhance immune response and protective antibody generation against four influenza virus strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:01.039Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention in adults (Phase 3 investigational)"}]},"trialDetails":[{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT05645900","phase":"PHASE3","title":"A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-02-06","conditions":"Influenza","enrollment":2772},{"nctId":"NCT05426174","phase":"PHASE1","title":"Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-06-09","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":233},{"nctId":"NCT06049927","phase":"PHASE3","title":"A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-09-16","conditions":"Seasonal Influenza","enrollment":3300},{"nctId":"NCT06744205","phase":"PHASE1, PHASE2","title":"A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-06","conditions":"Influenza, Healthy Volunteers","enrollment":1162},{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT05071313","phase":"PHASE3","title":"A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-10-04","conditions":"Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention","enrollment":777},{"nctId":"NCT05091307","phase":"PHASE3","title":"A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-11-02","conditions":"COVID-19 Prevention","enrollment":861},{"nctId":"NCT06134804","phase":"PHASE3","title":"A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-10-24","conditions":"Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention","enrollment":959},{"nctId":"NCT06342349","phase":"PHASE1","title":"A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-03-30","conditions":"Influenza","enrollment":300},{"nctId":"NCT06827873","phase":"NA","title":"Effect of Oral Supplements for Influenza Vaccine Response","status":"NOT_YET_RECRUITING","sponsor":"Tsinghua University","startDate":"2025-02","conditions":"Influenza Vaccine Response","enrollment":45},{"nctId":"NCT03849560","phase":"PHASE2, PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":"Influenza","enrollment":612},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT05245552","phase":"PHASE3","title":"A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-08-08","conditions":"Seasonal Influenza","enrollment":217},{"nctId":"NCT06385821","phase":"PHASE3","title":"A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2022-09-21","conditions":"Influenza, Influenza A, Influenza, Human","enrollment":824},{"nctId":"NCT05734040","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.","status":"COMPLETED","sponsor":"Osivax","startDate":"2023-05-10","conditions":"Influenza","enrollment":478},{"nctId":"NCT02677493","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-10","conditions":"Influenza","enrollment":1794},{"nctId":"NCT05512494","phase":"PHASE4","title":"Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-11-27","conditions":"Seasonal Influenza","enrollment":1260},{"nctId":"NCT05739474","phase":"PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children","status":"UNKNOWN","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2022-01-19","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":948},{"nctId":"NCT05062759","phase":"PHASE3","title":"Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-08-23","conditions":"Moderate to Severe Asthma","enrollment":70},{"nctId":"NCT05869201","phase":"PHASE2, PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-10-06","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":450},{"nctId":"NCT04192500","phase":"PHASE2","title":"Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years","status":"COMPLETED","sponsor":"Osivax","startDate":"2019-12-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT04001504","phase":"PHASE3","title":"Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-07-19","conditions":"Acute Coronary Syndrome","enrollment":1801},{"nctId":"NCT05494047","phase":"PHASE3","title":"Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-07-14","conditions":"Influenza, Vaccines","enrollment":1600},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT02480998","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-02","conditions":"Influenza, Human","enrollment":84},{"nctId":"NCT03926416","phase":"PHASE1","title":"Safety Study of Live Attenuated Influenza Vaccine, CodaVax","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2017-02-21","conditions":"Influenza","enrollment":125},{"nctId":"NCT03058692","phase":"PHASE2","title":"Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-09","conditions":"Influenza, Influenza Immunisation","enrollment":120},{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503},{"nctId":"NCT03564444","phase":"PHASE4","title":"D2560C00015 FluMist Annual Safety Study 2018","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2018-06-06","conditions":"Influenza, Healthy","enrollment":300},{"nctId":"NCT03859141","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-02-06","conditions":"Seasonal Influenza","enrollment":2340},{"nctId":"NCT03853993","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-01-23","conditions":"Seasonal Influenza","enrollment":2380},{"nctId":"NCT03826719","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-02-17","conditions":"Influenza","enrollment":100},{"nctId":"NCT03657719","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2018-10-01","conditions":"Influenza, Human","enrollment":105},{"nctId":"NCT03158038","phase":"PHASE4","title":"Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-05-30","conditions":"Influenza, Healthy","enrollment":300},{"nctId":"NCT03143101","phase":"PHASE4","title":"Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-05-08","conditions":"Influenza, Healthy","enrollment":200},{"nctId":"NCT03020628","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2016-10","conditions":"Influenza, Human","enrollment":171},{"nctId":"NCT02743117","phase":"PHASE4","title":"Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2016-05-02","conditions":"Influenza, Healthy","enrollment":301},{"nctId":"NCT02214225","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-08","conditions":"Influenza, Human","enrollment":3484},{"nctId":"NCT02473510","phase":"PHASE4","title":"Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2015-06","conditions":"Influenza, Healthy","enrollment":301},{"nctId":"NCT02915809","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults","status":"UNKNOWN","sponsor":"Green Cross Corporation","startDate":"2016-10","conditions":"Influenza, Human","enrollment":414},{"nctId":"NCT02710409","phase":"PHASE3","title":"A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2016-01","conditions":"Influenza","enrollment":3664},{"nctId":"NCT01992107","phase":"PHASE3","title":"Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Influenza","enrollment":2333},{"nctId":"NCT02621164","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-09","conditions":"Influenza, Human","enrollment":454},{"nctId":"NCT02434276","phase":"PHASE2","title":"Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2015-05","conditions":"Influenza","enrollment":450},{"nctId":"NCT02247362","phase":"PHASE1, PHASE2","title":"Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2014-11","conditions":"Influenza","enrollment":200},{"nctId":"NCT01859143","phase":"PHASE4","title":"Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2013-05","conditions":"Influenza, Healthy","enrollment":300},{"nctId":"NCT01810731","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya","status":"WITHDRAWN","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-04","conditions":"Influenza, Human, HIV, Malaria","enrollment":""},{"nctId":"NCT00860067","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-03","conditions":"Healthy or Stable Underlying Chronic Medical Condition","enrollment":1800},{"nctId":"NCT01091246","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2010-03","conditions":"Healthy or Stable Chronic Illness","enrollment":2312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Double Dose Quadrivalent Influenza Vaccine","genericName":"Double Dose Quadrivalent Influenza Vaccine","companyName":"Hospital Israelita Albert Einstein","companyId":"hospital-israelita-albert-einstein","modality":"Biologic","firstApprovalDate":"","aiSummary":"A quadrivalent influenza vaccine administered at double the standard dose to enhance immune response and protective antibody generation against four influenza virus strains. Used for Influenza prevention in adults (Phase 3 investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}